Dmg Montpellier Evaluation Stage
Posted on by admin
Dmg Montpellier Evaluation Stage Average ratng: 6,8/10 7993 votes
| Arm | Intervention/treatment |
|---|---|
| Experimental: Arm 1 Cohort A (Safety Evaluation):Atezolizumab + Obinutuzumab Relapsed/refractory FL and DLBCL participants will receive obinutuzumab alone on Days 1, 8, and 15 of Cycle 1 (Cycle length = 21 days), followed by atezolizumab and obinutuzumab on Day 1 of Cycles 2-8, and then atezolizumab alone on Day 1 of Cycle 9 and every cycle thereafter until unacceptable toxicities or disease progression. | Drug: Atezolizumab During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage. Drug: Obinutuzumab During safety evaluation stage, obinutuzumab will be administered as 1000 mg IV infusion. During expansion stage, obinutuzumab will be administered as either 1000 mg IV infusion or at dose decided from safety evaluation stage. |
| Experimental: Arm 1 Cohort B (Expansion): Atezolizumab + Obinutuzumab Relapsed/refractory FL participants will receive atezolizumab and obinutuzumab as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression. | Drug: Atezolizumab During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage. Drug: Obinutuzumab During safety evaluation stage, obinutuzumab will be administered as 1000 mg IV infusion. During expansion stage, obinutuzumab will be administered as either 1000 mg IV infusion or at dose decided from safety evaluation stage. |
| Experimental: Arm 1 Cohort C (Expansion): Atezolizumab + Obinutuzumab Relapsed/refractory DLBCL participants will receive atezolizumab and obinutuzumab as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression. | Drug: Atezolizumab During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage. Drug: Tazemetostat Tazemetostat 800 mg will be administered orally, twice daily, on Days 1 to 21. |
| Experimental: Arm 2 Cohort D (Safety Evaluation):Atezolizumab + Tazemetostat Relapsed/refractory DLBCL participants will receive atezolizumab (on Day 1) and tazemetostat (on Days 1-21) of each 21-day cycle until unacceptable toxicities or disease progression. | Drug: Atezolizumab During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage. Drug: Tazemetostat Tazemetostat 800 mg will be administered orally, twice daily, on Days 1 to 21. |
| Experimental: Arm 2 Cohort E (Expansion): Atezolizumab + Tazemetostat Relapsed/refractory DLBCL participants will receive atezolizumab and tazemetostat as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression. | Drug: Atezolizumab During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage. Drug: Tazemetostat Tazemetostat 800 mg will be administered orally, twice daily, on Days 1 to 21. |
Revision Stage
Upper stage will occur about nine minutes after liftoff, followed by the first firing of the upper stage. The upper stage – carrying four 715-kg Galileo satellites – will fly in ballistic configuration for th ree hours and eight minutes, after which a second upper stage firing will place it into circular separation orbit. The mean time to Stage V for KA rats (354.1 10.7 min) was significantly (p 0.0001) longer than for Li/pilocarpine rats (187.9 17.4 min.) but the mean escape time at Stage V was not significantly different. Conclusion: Prolonged SE results in a marked progressive impairment of visual-spatial memory and learning.